Sponsored

Chimeric's (ASX:CHM) Cancer Cell Therapy Trial Opens for Patient Enrolment at University of Pennsylvania

September 11, 2024 03:42 AM CEST | By Aditi Sarkar
 Chimeric's (ASX:CHM) Cancer Cell Therapy Trial Opens for Patient Enrolment at University of Pennsylvania
Image source: Company update

Highlights

  • The University of Pennsylvania will enrol patients in the Phase 1/2 multi-centre clinical trial for the CHM CDH17 cell therapy.
  • This study aims to determine the optimal Phase 2 dosage of CHM CDH17 and evaluate its safety and efficacy.
  • In August 2024, CHM announced the enrolment of the first patient for this clinical trial.
  • Additional clinical trial sites are expected to start enrolling participants in the second half of 2024.

Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced positive developments regarding its CHM CDH17 cell therapy. World-renowned cell therapy centre, the University of Pennsylvania is now enrolling patients in the Phase 1/2 multi-centre clinical trial for this therapy.

This two-stage study aims to determine the optimal Phase 2 dosage of CHM CDH17 and assess its safety and efficacy in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

On 28 August 2024, CHM announced the enrolment of the first patient in this clinical trial.

Image source: Company update

Reflecting on the development, Jennifer Eads, MD, the study’s principal investigator from the University of Pennsylvania, said, “After over a decade of development here at Penn, it is thrilling to be advancing CHM CDH17 as a potential new medicine for cancer patients.”

Additional clinical trial sites are expected to begin enrolling participants in the latter half of 2024.

Chimeric Therapeutics currently has a diversified portfolio, including first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies. Its assets are being developed across multiple oncology-related disease areas. The company has three clinical-stage programs.

CHM shares trade higher

CHM shares saw a rise of over 6.6%, trading at AU$0.016, at the time of writing on 11 September 2024.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles